Charles Schwab
CTKB icon

Charles Schwab’s Cytek Biosciences CTKB Stock Holding History

Charles Schwab’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.75M Sell
1,073,253
-31,348
-3% -$134K ﹤0.01% 2508
2026
Q1 		$4.83M Buy
1,104,601
+10,062
+0.9% +$47.5K ﹤0.01% 2417
2025
Q4 		$5.53M Sell
1,094,539
-10,482
-0.9% -$48.7K ﹤0.01% 2402
2025
Q3 		$3.83M Buy
1,105,021
+195,431
+21% +$734K ﹤0.01% 2543
2025
Q2 		$3.09M Sell
909,590
-195,299
-18% -$651K ﹤0.01% 2523
2025
Q1 		$4.43M Buy
1,104,889
+41,899
+4% +$217K ﹤0.01% 2318
2024
Q4 		$6.9M Buy
1,062,990
+32,028
+3% +$191K ﹤0.01% 2180
2024
Q3 		$5.71M Buy
1,030,962
+113,127
+12% +$641K ﹤0.01% 2297
2024
Q2 		$5.12M Buy
917,835
+16,842
+2% +$101K ﹤0.01% 2350
2024
Q1 		$6.05M Buy
900,993
+20,955
+2% +$166K ﹤0.01% 2217
2023
Q4 		$8.03M Buy
880,038
+44,345
+5% +$279K ﹤0.01% 2107
2023
Q3 		$4.61M Buy
835,693
+136,201
+19% +$1.09M ﹤0.01% 2297
2023
Q2 		$5.97M Buy
699,492
+30,818
+5% +$276K ﹤0.01% 2162
2023
Q1 		$6.15M Buy
668,674
+613
+0.1% +$6.59K ﹤0.01% 2106
2022
Q4 		$6.82M Buy
668,061
+13,399
+2% +$180K ﹤0.01% 2045
2022
Q3 		$9.64M Buy
654,662
+339,406
+108% +$4.41M ﹤0.01% 1856
2022
Q2 		$3.38M Buy
315,256
+25,410
+9% +$253K ﹤0.01% 2362
2022
Q1 		$3.13M Buy
289,846
+184,142
+174% +$2.49M ﹤0.01% 2490
2021
Q4 		$1.73M Buy
105,704
+2,714
+3% +$56.8K ﹤0.01% 2746
2021
Q3 		$2.21M Buy
+102,990
New +$2.42M ﹤0.01% 2676

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Charles Schwab's CTKB Position: Q2 2026 in Review

Charles Schwab reduced its Cytek Biosciences (CTKB) stake by 2.8% in Q2 2026, selling an estimated $134K and leaving 1,073,253 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2508.

Charles Schwab first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $9.64M in Q3 2022. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Charles Schwab held 1,073,253 shares of Cytek Biosciences worth $4.75M as of Q2 2026.
  • Charles Schwab sold 31,348 Cytek Biosciences shares in Q2 2026, an estimated $134K.
  • Cytek Biosciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2508 holding.
  • Charles Schwab first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • Charles Schwab's Cytek Biosciences position peaked at $9.64M in Q3 2022.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.